was read the article
array:24 [ "pii" => "S1578219018303524" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018303983" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.08.002" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 311 "formatos" => array:2 [ "HTML" => 170 "PDF" => 141 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentario Editorial</span>" "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219018303524" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303983?idApp=UINPBA000044" "url" => "/00017310/0000010900000009/v1_201811020614/S0001731018303983/v1_201811020614/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219018303196" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.05.032" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2004" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:767-70" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinion Article</span>" "titulo" => "What We Know About the Clinical Course of Nonsegmental Vitiligo: Experience of a Researcher and a Dermatologist" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "767" "paginaFinal" => "770" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experiencia de un investigador y un dermatólogo sobre el conocimiento del curso clínico del vitiligo no segmentario" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.L. Peralta-Pedrero, F. Jurado Santa-Cruz" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M.L." "apellidos" => "Peralta-Pedrero" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Jurado Santa-Cruz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018302898" "doi" => "10.1016/j.ad.2018.05.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018302898?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303196?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303196/v1_201811020640/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219018303172" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "HTML" => 2 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Local Experience with Vismodegib" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vismodegib, una experiencia local" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Pasquali" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303363" "doi" => "10.1016/j.ad.2018.06.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303363?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.assets" ] "asociados" => array:1 [ 0 => array:19 [ "pii" => "S1578219018303238" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.09.011" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2040" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Actas Dermosifiliogr. 2018;109:771-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 11 "formatos" => array:2 [ "HTML" => 7 "PDF" => 4 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>" "titulo" => "Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "771" "paginaFinal" => "776" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1819 "Ancho" => 3083 "Tamanyo" => 264119 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the treatment of chronic spontaneous urticaria with omalizumab. Abbreviations: UAS7, weekly Urticaria Activity Score; UCT, Urticaria Control Test.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa, A. Gimenez Arnau" "autores" => array:23 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Spertino" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Curto Barredo" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Rozas Muñoz" ] 3 => array:2 [ "nombre" => "I." "apellidos" => "Figueras Nart" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Serra Baldrich" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Bonfill-Ortí" ] 6 => array:2 [ "nombre" => "V." "apellidos" => "Expósito-Serrano" ] 7 => array:2 [ "nombre" => "A." "apellidos" => "Guilabert" ] 8 => array:2 [ "nombre" => "G." "apellidos" => "Melé Ninot" ] 9 => array:2 [ "nombre" => "M." "apellidos" => "Villar Buil" ] 10 => array:2 [ "nombre" => "J." "apellidos" => "Garcias Ladaria" ] 11 => array:2 [ "nombre" => "X." "apellidos" => "García Navarro" ] 12 => array:2 [ "nombre" => "M." "apellidos" => "Vilavella" ] 13 => array:2 [ "nombre" => "I." "apellidos" => "Bielsa Marsol" ] 14 => array:2 [ "nombre" => "G." "apellidos" => "Aparicio Ortiz" ] 15 => array:2 [ "nombre" => "C." "apellidos" => "Baliu Piqué" ] 16 => array:2 [ "nombre" => "A." "apellidos" => "Álvarez Abella" ] 17 => array:2 [ "nombre" => "N." "apellidos" => "Lamas Domenech" ] 18 => array:2 [ "nombre" => "J.M." "apellidos" => "Mascaró" ] 19 => array:2 [ "nombre" => "S." "apellidos" => "Gómez" ] 20 => array:2 [ "nombre" => "J.I." "apellidos" => "Torné Gutiérrez" ] 21 => array:2 [ "nombre" => "A." "apellidos" => "Vicente Villa" ] 22 => array:2 [ "nombre" => "A." "apellidos" => "Gimenez Arnau" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303594" "doi" => "10.1016/j.ad.2018.07.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303594?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303238?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303238/v1_201811020640/en/main.assets" ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:3 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" "email" => array:1 [ 0 => "ismenios@hotmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Dermatología, Hospital Universitario San Cecilio, Granada, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up to 4 times that dose. The introduction of omalizumab into the therapeutic arsenal for CSU brought about a real revolution in the management of this condition. However, the dose recommended in the Summary of Product Characteristics—based on the results of pivotal studies carried out as part of the approval process—is 300 mg/mo for a period of up to 6 months. In the present issue, the Catalan-Balearic working group presents a treatment algorithm to guide the use of omalizumab in the management of CSU. They discuss the various aspects of management related to the rational and evidence-based use of this drug, including candidate population, monitoring tools (Urticaria Activity Score 7 [UAS7] and Urticarial Control Test [UCT]), starting dose and dose adjustment as well as the definition of response and response time.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In a novel approach, the authors of the algorithm propose the use of an increased dose of 450 or 600 mg every 4 weeks if the licensed doses do not achieve adequate control of disease activity—defined as a UAS7 of 6 or less. A study by the Catalan workgroup showed that 21% of patients require the increased dose to achieve a UAS7 of 6 or less and that 7% did not achieve disease control even with the higher dose. The predictors of partial response to 300 mg and the need for higher doses included prior treatment with ciclosporin, obesity, and age under 57 years.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">This algorithm is of particular interest to dermatologists working in clinical practice.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Ruiz-Villaverde R. Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica. Actas Dermosifiliogr. 2018;109:766.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib0015" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea. Documento de consenso de la “Xarxa d’Urticària Catalana i Balear”" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Spertino" 1 => "E. Rozas Muñoz" 2 => "L. Curto Barredo" 3 => "I. Figueras Nart" 4 => "A. Gimenez Arnau" 5 => "E. Serra Baldrich" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2018.07.005" "Revista" => array:3 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2018" "volumen" => "109" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0020" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Curto-Barredo" 1 => "J. Spertino" 2 => "I. Figueras-Nart" 3 => "V. Expósito-Serrano" 4 => "A. Guilabert" 5 => "G. Melé-Ninot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.16379" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2018" "volumen" => "179" "paginaInicial" => "210" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29368377" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 6 | 8 | 14 |
2024 October | 71 | 47 | 118 |
2024 September | 70 | 27 | 97 |
2024 August | 81 | 53 | 134 |
2024 July | 58 | 30 | 88 |
2024 June | 69 | 22 | 91 |
2024 May | 78 | 31 | 109 |
2024 April | 68 | 19 | 87 |
2024 March | 63 | 25 | 88 |
2024 February | 48 | 28 | 76 |
2024 January | 48 | 31 | 79 |
2023 December | 46 | 13 | 59 |
2023 November | 84 | 25 | 109 |
2023 October | 45 | 22 | 67 |
2023 September | 35 | 31 | 66 |
2023 August | 33 | 9 | 42 |
2023 July | 44 | 29 | 73 |
2023 June | 38 | 26 | 64 |
2023 May | 38 | 33 | 71 |
2023 April | 28 | 22 | 50 |
2023 March | 39 | 27 | 66 |
2023 February | 34 | 21 | 55 |
2023 January | 37 | 23 | 60 |
2022 December | 42 | 45 | 87 |
2022 November | 20 | 23 | 43 |
2022 October | 26 | 18 | 44 |
2022 September | 23 | 33 | 56 |
2022 August | 21 | 28 | 49 |
2022 July | 32 | 37 | 69 |
2022 June | 26 | 28 | 54 |
2022 May | 29 | 44 | 73 |
2022 April | 32 | 29 | 61 |
2022 March | 37 | 42 | 79 |
2022 February | 24 | 22 | 46 |
2022 January | 31 | 33 | 64 |
2021 December | 41 | 37 | 78 |
2021 November | 39 | 47 | 86 |
2021 October | 43 | 70 | 113 |
2021 September | 35 | 42 | 77 |
2021 August | 39 | 42 | 81 |
2021 July | 32 | 45 | 77 |
2021 June | 30 | 39 | 69 |
2021 May | 42 | 53 | 95 |
2021 April | 97 | 72 | 169 |
2021 March | 70 | 45 | 115 |
2021 February | 55 | 43 | 98 |
2021 January | 49 | 51 | 100 |
2020 December | 36 | 42 | 78 |
2020 November | 41 | 38 | 79 |
2020 October | 24 | 24 | 48 |
2020 September | 39 | 22 | 61 |
2020 August | 26 | 26 | 52 |
2020 July | 19 | 24 | 43 |
2020 June | 32 | 28 | 60 |
2020 May | 18 | 16 | 34 |
2020 April | 22 | 12 | 34 |
2020 March | 20 | 9 | 29 |
2020 February | 1 | 0 | 1 |
2019 May | 1 | 0 | 1 |